Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Amortization of Deferred Charges: 2019-2020

Historic Amortization of Deferred Charges for Akebia Therapeutics (AKBA) over the last 1 years, with Mar 2020 value amounting to -$647,000.

  • Akebia Therapeutics' Amortization of Deferred Charges fell 5.37% to -$647,000 in Q1 2020 from the same period last year, while for Mar 2020 it was -$2.3 million, marking a year-over-year change of. This contributed to the annual value of -$2.2 million for FY2019, which is N/A change from last year.
  • Latest data reveals that Akebia Therapeutics reported Amortization of Deferred Charges of -$647,000 as of Q1 2020, which was down 16.37% from -$556,000 recorded in Q4 2019.
  • In the past 5 years, Akebia Therapeutics' Amortization of Deferred Charges registered a high of -$483,000 during Q2 2019, and its lowest value of -$647,000 during Q1 2020.
  • Over the past 2 years, Akebia Therapeutics' median Amortization of Deferred Charges value was -$576,000 (recorded in 2019), while the average stood at -$575,200.
  • Data for Akebia Therapeutics' Amortization of Deferred Charges shows a maximum YoY fell of 5.37% (in 2020) over the last 5 years.
  • Over the past 2 years, Akebia Therapeutics' Amortization of Deferred Charges (Quarterly) stood at -$556,000 in 2019, then dropped by 5.37% to -$647,000 in 2020.
  • Its Amortization of Deferred Charges was -$647,000 in Q1 2020, compared to -$556,000 in Q4 2019 and -$576,000 in Q3 2019.